DSM Venturing

Investor type Corporate Venture Capital

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 66
Average round size
info
The average size of a deal this fund participated in
$6M
Portfolio companies 50
Rounds per year 3.30
Lead investments 27
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.24
Exits 9
Key employees 6
Stages of investment
Early Stage Venture
Late Stage Venture
Seed

Areas of investment

  • Health Care
  • Biotechnology
  • Manufacturing
  • Medical Device
  • Wellness
Summary

DSM Venturing is the famous VC, which was founded in 1902. The leading representative office of defined VC is situated in the Urmond. The company was established in Europe in The Netherlands.

The usual things for fund are deals in the range of 5 - 10 millions dollars. This DSM Venturing works on 15 percentage points less the average amount of lead investments comparing to the other organizations. Speaking about the real fund results, this VC is 23 percentage points more often commits exit comparing to other organizations. The high activity for fund was in 2018. Despite it in 2019 the fund had an activity. The fund is constantly included in 2-6 investment rounds annually. The increased amount of exits for fund were in 2018.

For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. Among the various public portfolio startups of the fund, we may underline Segetis, Verdezyne, Raycatch Besides, a startup needs to be aged 6-10 years to get the investment from the fund. The fund has no exact preference in a number of founders of portfolio startups. When startup sums 4 of the founder, the probability for it to get the investment is little. We can highlight the next thriving fund investment areas, such as Medical, Health Care.

Besides them, we counted 2 critical employees of this fund in our database.

The standard case for the fund is to invest in rounds with 2-3 partakers. Despite the DSM Venturing, startups are often financed by BASF Venture Capital, Burrill & Company, Prelude Trust. The meaningful sponsors for the fund in investment in the same round are BASF Venture Capital, Burrill & Company, Prelude Trust. In the next rounds fund is usually obtained by Burrill & Company, BASF Venture Capital, Prelude Trust.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of DSM Venturing:
Typical Co-investors
DSM Venturing is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after DSM Venturing:

Funds with similar focus

Funds from The Netherlands
Funds with similar focus located in The Netherlands:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Rootine

Developer APIs
Dietary Supplements
Health Care
Nutraceutical
Nutrition
Personal Health
Wellness
$3M10 Aug 2021 Nashville, Tennessee, United States

Prenexus Health

Fitness
Manufacturing
Wellness
$15M21 Jul 2021 Gilbert, Arizona, United States

Additive Manufacturing Technologies

3D Printing
Industrial Manufacturing
Machinery Manufacturing
$15M02 Jul 2021 Sheffield, England, United Kingdom

Leading Edge Equipment Technologies

Industrial Engineering
Manufacturing
Renewable Energy
$2M01 Jul 2021 Massachusetts, United States

Food and Beverage
Food Processing
Innovation Management
$47M23 Mar 2021 Delft, South Holland, Netherlands

Novum Medical

Biotechnology
Health Care
Manufacturing
Medical Device
Nanotechnology
11 Mar 2021 Woburn, Massachusetts, United States

Additive Manufacturing Technologies

3D Printing
Industrial Manufacturing
Machinery Manufacturing
$3M02 Mar 2021 England

Frontier Nutrition

Consumer Goods
Manufacturing
Packaging Services
$6M03 Feb 2021 New Haven, Connecticut, United States

NutriLeads

Food and Beverage
Food Processing
Health Care
Organic Food
$7M30 Aug 2020 Gelderland
News
Meatable Raises $47 Million Series A to Continue Scaling Trajectory and Expand its Product Portfolio with Beef

– Meatable has closed $47m in Series A funding.
– Consortium consists of Dr. Rick Klausner, Section 32, Dr. Jeffrey Leiden, and DSM Venturing.
– Existing investors, such as BlueYard Capital, Agronomics, Humboldt, and Taavet Hinrikus, show continued support.
– Meatable sees great potential in its technology and is betting on the company to solve the industry’s scalability and speed-to-market challenges with its patented opti-ox™ technology.
– Meatable aims to produce cultivated meat for which no animals are slaughtered, fewer GHG emissions are released, and less land and water are required.

Deep Branch Announces EUR 8M Series A Round led by Novo Holdings and DSM Venturing, Paving the Way for Commercial-Scale Production Facility

– Deep Branch has announced an €8M Series A round.
– The investment was led by Novo Holdings and DSM Venturing, with participation from Total Carbon Neutrality Ventures and Barclays Sustainable Impact Capital.
– Deep Branch addresses both the sustainability of animal farming and the reduction of carbon dioxide emissions with their CO2-to-protein technology, creating the first scalable path for a truly sustainable protein generation process from a waste product.
– The Series A financing will enable the completion of Deep Branch’s Scale-Up Hub at the Brightlands Chemelot Campus (Limburg, NL), producing the first pilot-scale batches of Proton™ for full nutritional validation with Europe’s leading feed producers, including BioMar and AB Agri.
– It will also enable the company to inform key engineering design work for its first commercial scale production facility.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent DSM Venturing?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: